Curosurf poractant alfa: Postmarketing study data

A retrospective analysis of hospital discharge data from 14,173 preterm infants with RDS who were treated with 1 of 3 surfactants between 2005-09 showed Curosurf significantly reduced the risk of death by 49.6% vs. Infasurf calfactant (p=0.043) and non-significantly reduced the risk of death by 37% vs. Survanta beractant (p=0.053). There were no significant differences in mortality observed between Infasurf and Survanta (p=0.626). Additionally, the unadjusted mortality rate for Curosurf was 3.6% vs. 6% and 4.6% for Infasurf and Survanta, respectively. Data were published in the Journal of Perinatology. ...